GlassScriptPhysician profile
Minh Q Le
NPI 1629203724
$10,384.44
in general payments reported to CMS, 2019-2025
44 companies · $2,075 in 2025
The $2,075 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $996 · 2020: $1,337 · 2021: $1,152 · 2022: $1,006 · 2023: $2,155 · 2024: $1,664 · 2025: $2,075.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,848 · Education: $45.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,848.35 |
| Education | $45.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,403.56 | 2020-2025 | |
| Novo Nordisk INC | $1,189.87 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $1,151.07 | 2019-2024 | Jardiance, Mounjaro, Zepbound |
| Pfizer INC. | $894.19 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $772.67 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $764.49 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $672.05 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $373.89 | 2023-2025 | |
| Allergan, INC. | $362.43 | 2019-2020 | |
| Amgen INC. | $314.69 | 2019-2024 | Otezla, Repatha |
| Merck Sharp & Dohme LLC | $275.91 | 2019-2024 | Gardasil 9, Belsomra, Vaxneuvance |
| Sanofi-Aventis U.S. LLC | $274.77 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $181.07 | 2020-2024 | Xifaxan, Trulance |
| Astellas Pharma US INC | $170.37 | 2023-2025 | Veozah |
| Abbott Laboratories | $166.14 | 2019-2024 | Freestyle Libre, I-Stat |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Minh Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.